摘要
Abstract
Objective:To evaluate the clinical outcomes,toxicities and prognostic factors of cetuximab plus intensity-modulated radiotherapy (IMRT)with chemotherapy for nasopharyngeal carcinoma(NPC).Methods:From March 2006 to March 2011,72 patients with stageⅡ~Ⅳ NPC without distant metastasis were included in our study.Cetuximab was administered at an initial dose of 400 mg/m2 followed by weekly doses of 250 mg/m2 .All patients received IMRT plus induction and/or concurrent chemotherapy.Results:With a median follow-up of 60.5 months(5 ~110 months),the 3,5-year locoregional recurrence-free survival (LRRFS),distant metastasis free survival(DMFS),progression-free survival (PFS)and overall survival(OS)were 86.1%,75.4%;79.2%,67.9%;77.8%,66.7% and 88.9%,76.7%,respectively.The 5-year PFS and OS were 83.3% and 97.1% for stageⅡ~Ⅲ patients compared with 51.7% and 58.3% for stage Ⅳ patients.Four patients experienced locoregional failure and distant metastasis occurred in 17 patients.Fourteen patients died,among them,8 died of distant metastasis.Tumor stage was a significant prognostic factor for PFS and OS(P =0.0146;P =0.0021).Grade 3 and 4 oral mucositis were found in 62.5% and 4.2% patients,respectively.Temporal lobe injure was observed in 14 patients.Conclusion:Cetuximab plus IMRT with chemotherapy for NPC is effective and the adverse events are acceptable.Prospective randomized controlled trials with larger sample size are expected in the future.关键词
鼻咽癌/西妥昔单抗/适形调强放疗/临床疗效/预后因素Key words
Nasopharyngeal Carcinoma/Cetuximab/Intensity-modulated Radiotherapy/Clinical Outcome/Prognostic Factors分类
医药卫生
